Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). uri icon

authors

  • Smolderen, Kim G
  • Boland, Joanna
  • Michael Nanna, MD, MHS
  • Mena-Hurtado, Carlos
  • Zhao, Zhenxiang
  • Michalak, Wojciech
  • Faurby, Mads
  • Smolarz, B Gabriel
  • Kosiborod, Mikhail N
  • Song, Jinlin
  • Chen, Yan

publication date

  • September 9, 2025